* SunPharm Corp., of Jacksonville, Fla., reported results from a Phase II multicenter trial of diethylhomospermine (DEHOP) in AIDS patients with uncontrolled, refractory diarrhea. Results showed an overall response rate of slightly better than 80 percent. DEHOP is an analogue of naturally occurring, essential intracellular polyamine compounds and inhibits the secretory and motility aspects of diarrhea. The product is in Phase I trials for cancer and ulcerative colitis.

* NaPro Biotherapeutics Inc., of Boulder, Colo., said it closed on the private placement of $5 million in convertible preferred stock. The shares will be sold at $1,000 per share and are entitled to quarterly dividends at 5 percent per year. The company plans to use the proceeds for general corporate purposes.

No Comments